Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.65 |
| ▸ | FOS | P01100 | 2/20 | 0.48 |
| ▸ | JUN | P05412 | 2/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746122 | 0.91 | GFPT1 (0.67) | GFPT1FOSJUNDPP4PDE10A | |
| SCHEMBL5744435 | 0.91 | GFPT1 (0.64) | GFPT1FOSJUNS1PR1DPP4 | |
| Trifluoroacetic Acid SCHEMBL5745098 | 0.90 | GFPT1 (0.66) | GFPT1FOSJUNS1PR1DPP4 | |
| SCHEMBL1366610 | 0.90 | GFPT1 (0.67) | GFPT1PTGDR2 | |
| SCHEMBL5744819 | 0.88 | GFPT1 (0.69) | GFPT1DPP4PDE10APTGDR2APAF1 | |
| Trifluoroacetic Acid SCHEMBL6108469 | 0.88 | GFPT1 (0.70) | GFPT1FOSJUNDPP4PTGDR2 | |
| SCHEMBL5745274 | 0.87 | GFPT1 (0.68) | GFPT1DPP4PDE10APTGDR2APAF1 | |
| Hydrochloric Acid SCHEMBL5742666 | 0.86 | GFPT1 (0.67) | GFPT1DPP4PDE10APTGDR2APAF1 | |
| Trifluoroacetic Acid SCHEMBL5768365 | 0.86 | GFPT1 (0.70) | GFPT1FOSJUNDPP4PDE10A | |
| SCHEMBL1367662 | 0.85 | GFPT1 (0.66) | GFPT1FOSJUNDPP4PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100540537-C | GFAT inhibitors | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | disclosed |
| US-7067529-B2 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1791581-A | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | CN | disclosed |
| EP-1631551-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | BOLIN DAVID ROBERT (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004101528-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | GFPT1, GLS2, GLS | GFPT1 1/4885FOS 936/4885JUN 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.